GlassScriptPhysician profile
Amanda Rae Ingram
NPI 1073044038
$4,426.89
in general payments reported to CMS, 2019-2025
24 companies · $798 in 2025
The $798 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $49.78 · 2022: $971 · 2023: $1,018 · 2024: $1,589 · 2025: $798.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,063 · Travel and Lodging: $1,343.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,062.90 |
| Travel and Lodging | $1,342.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,116.22 | 2022-2025 | Interstim |
| Coloplast Corp | $1,112.49 | 2024 | |
| Procept Biorobotics Corporation | $1,025.72 | 2023-2025 | Aquabeam Robotic System, Aquabeam System |
| Teleflex LLC | $152.04 | 2023-2025 | Urolift, Barrigel |
| Boston Scientific Corporation | $133.43 | 2021-2024 | Rezum Generator, Lynx System, Advantage System |
| Abbvie INC. | $131.40 | 2024-2025 | |
| Caldera Medical, INC | $130.75 | 2023 | Desara |
| Sumitomo Pharma America, INC. | $107.58 | 2024-2025 | Gemtesa |
| Smith+Nephew, INC. | $88.34 | 2022-2025 | Stravix |
| Olympus America INC. | $87.78 | 2024-2025 | Itind System, Uropass |
| Merck Sharp & Dohme LLC | $54.96 | 2023-2024 | Keytruda, Lynparza |
| Astellas Pharma US INC | $44.51 | 2022 | |
| Janssen Biotech, INC. | $38.90 | 2022-2023 | Erleada |
| Calyxo, INC. | $26.34 | 2024 | Cvac Aspiration System |
| Blue Earth Diagnostics | $24.35 | 2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo USA, INC. | $20.54 | 2025 | Aveed, Xiaflex |
| Profound Medical Corp. | $19.83 | 2025 | Tulsa-Pro |
| Pfizer INC. | $19.53 | 2024 | |
| Bard Peripheral Vascular, INC. | $18.04 | 2025 | Model 200 Theraseed Palladium-103 In Readylink |
| Myriad Genetic Laboratories, INC. | $17.05 | 2025 | Prolaris |
| Urovant Sciences INC | $16.29 | 2022 | |
| Dexcom, INC. | $14.07 | 2025 | Dexcom G6 Transmitter |
| Photocure INC | $13.45 | 2022 | |
| Novo Nordisk INC | $13.28 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Ingram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.